

AUTHORIZATION TO ACT IN A REPRESENTATIVE CAPACITY


In re Application of:	McGee, et al.
Patent No.:	7,041,691
Issued:	May 9, 2006
Application No.:	09/606,433
Filed:	June 28, 2000
Title:	COMPOUNDS FOR THE MODULATION OF PPARY ACTIVITY
Attorney Docket No.:	11134-121-999
Art Unit:	1625

The practitioner named below is authorized to conduct interviews and has the authority to bind the principal concerned. Furthermore, the practitioner is authorized to file correspondence in the above-identified application pursuant to 37 CFR 1.34:

Firm Name	Customer Number
JONES DAY	20583

This is not a Power of Attorney to the above-named practitioner. Accordingly, the practitioner named above does **not** have authority to sign a request to change the correspondence address, a request for an express abandonment, a disclaimer, a power of attorney, or other document requiring the signature of the applicant, assignee of the entire interest or an attorney of record. If appropriate, a separate Power of Attorney to the above-named practitioner should be executed and filed in the United States Patent and Trademark Office.

SIGNATURE of Practitioner of Record

Name:	Christopher J. Smith		
Signature:		Date:	9/7/07
Registration Number:	40,179	Telephone:	650-244-2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: McGee et al.

Docket No.: 11134-121-999

Patent No. 7,041,691

Group Art Unit: 1625

Issued: May 9, 2006

Examiner: Seaman, D. Margaret M.

Serial No. 09/606,433

Filed: June 28, 2000

For: COMPOUNDS FOR THE MODULATION OF PPARY ACTIVITY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. 3.73(b)

Amgen Inc. (hereinafter "Amgen"), a corporation of the State of Delaware having a place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, is the assignee of the entire right, title, and interest in the above-identified U.S. patent application. A chain of title from the inventors of the above-identified application to Amgen Inc. is shown below.

1. From inventors Lawrence R. McGee, Jonathan B. Houze, and Steven M. Rubenstein To: Tularik, Inc. the assignment recorded December 1, 2000, in the USPTO at Reel 011309, Frame 0253.

2. From Tularik, Inc. To: Arrow Acquisition, LLC the assignment April 11, 2005, in the USPTO at Reel 015886, Frame 0253.

3. From Arrow Acquisition, LLC To: Amgen SF, LLC the assignment recorded April 11, 2005, in the USPTO at Reel 015886, Frame 0258.

4. From Tularik, Inc. To: Arrow Acquisition, LLC the assignment June 7, 2005, in the USPTO at Reel 016309, Frame 0003.

5. From Arrow Acquisition, LLC To: Amgen SF, LLC the assignment recorded June 7, 2005, in the USPTO at Reel 016309, Frame 0812.

6. From Amgen SF, LLC To: Amgen Inc. the assignment recorded April 11, 2005, in the USPTO at Reel 015886, Frame 0263.

The undersigned, whose title is supplied below, is empowered to sign this statement on behalf of Amgen.

**REVOCATION OR PREVIOUS POWER OF ATTORNEY AND
NEW POWER OF ATTORNEY BY ASSIGNEE**

Amgen hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners at Customer Number **21069** to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS

Please send all future correspondence and direct telephone calls to Customer Number **20583**.

Respectfully submitted,

Date Aug. 29, 2007

By:

Stuart L. Watt
Stuart L. Watt
Vice President, Law
AMGEN INC.

